Audentes Therapeutics, Inc (BOLD) related to its sale to Astellas Pharma, Inc. Under the terms of the Agreement, Audentes shareholders will have the right to receive $60.00 in cash for each Audentes common stock owned.
Audentes Therapeutics, Inc (BOLD) related to its sale to Astellas Pharma, Inc. Under the terms of the Agreement, Audentes shareholders will have the right to receive $60.00 in cash for each Audentes common stock owned.